Detalhe da pesquisa
1.
Development of clinical screening tool for exocrine pancreatic insufficiency in patients with definite chronic pancreatitis.
Pancreatology
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693039
2.
Early initiation of glecaprevir/pibrentasvir after transplantation of HCV-viremic kidneys into HCV-negative recipients is associated with normalization in the altered inflammatory milieu.
Clin Transplant
; 37(4): e14926, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36752566
3.
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
J Hepatol
; 75(4): 820-828, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34023351
4.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365309
5.
Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
J Am Soc Nephrol
; 31(11): 2678-2687, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32843477
6.
Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
J Infect Dis
; 221(2): 223-231, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504702
7.
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Gastroenterology
; 157(6): 1506-1517.e1, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31401140
8.
Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
J Pharmacol Exp Ther
; 370(2): 278-287, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31167814
9.
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Hepatology
; 67(4): 1253-1260, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29152781
10.
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Hepatology
; 67(2): 514-523, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28926120
11.
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
Eur J Clin Pharmacol
; 75(2): 217-226, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30341499
12.
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.
Antimicrob Agents Chemother
; 62(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263061
13.
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Clin Gastroenterol Hepatol
; 16(3): 417-426, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28951228
14.
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Hepatology
; 66(2): 389-397, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28128852
15.
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
J Hepatol
; 67(2): 263-271, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28412293
16.
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Antimicrob Agents Chemother
; 61(10)2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28807904
17.
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Gastroenterology
; 151(4): 651-659.e1, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27456384
18.
High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.
Liver Int
; 36(8): 1125-32, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26778412
19.
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Antimicrob Agents Chemother
; 60(3): 1546-55, 2015 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26711747
20.
Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.
Lung
; 193(1): 3-11, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25318864